Literature DB >> 25583841

Subclinical central inflammation is risk for RIS and CIS conversion to MS.

S Rossi1, C Motta1, V Studer2, G Macchiarulo2, G Germani2, A Finardi3, R Furlan3, G Martino3, D Centonze4.   

Abstract

BACKGROUND: Subtle diffuse intrathecal inflammation is undetectable by conventional neuroimaging, and could influence multiple sclerosis (MS) disease course.
OBJECTIVE: To explore the role of subclinical persisting intrathecal inflammation in radiologically isolated syndrome (RIS) or clinically isolated syndrome (CIS) conversion to MS, and in early MS disease reactivation.
METHODS: One-hundred ninety-three subjects with RIS, CIS, relapsing-remitting (RR), or primary progressive (PP) MS were included, along with 76 matched controls. Cerebrospinal fluid (CSF) levels of interleukin-8 (IL-8), a major proinflammatory cytokine, were measured as a biomarker of intrathecal inflammation. Patients were followed up for 2 years. Clinical and imaging measures of disease progression were recorded.
RESULTS: High central contents of IL-8 were associated to clinical progression in subjects with RIS, and to the risk of conversion to MS in subjects with CIS. Asymptomatic intrathecal inflammation placed subjects at risk for MS conversion, even regardless lesion load. CSF IL-8 levels were higher in RR MS with high disease activity. Higher number of relapses in the first two years since diagnosis and shorter first inter-attack intervals were observed in patients with high levels of IL-8.
CONCLUSION: IL-8 might provide utility in determining the presence of active intrathecal inflammation, and could be important in diagnostically undefined cases.
© The Author(s), 2015.

Entities:  

Keywords:  Clinically isolated syndrome; IL-8; intrathecal inflammation; progression; radiologically isolated syndrome; relapse

Mesh:

Substances:

Year:  2015        PMID: 25583841     DOI: 10.1177/1352458514564482

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  13 in total

1.  Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course.

Authors:  Mario Stampanoni Bassi; Ennio Iezzi; Doriana Landi; Fabrizia Monteleone; Luana Gilio; Ilaria Simonelli; Alessandra Musella; Georgia Mandolesi; Francesca De Vito; Roberto Furlan; Annamaria Finardi; Girolama A Marfia; Diego Centonze; Fabio Buttari
Journal:  J Neurol       Date:  2018-08-28       Impact factor: 4.849

Review 2.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

Review 3.  Treatment Considerations in the Radiologically Isolated Syndrome.

Authors:  Naila Makhani
Journal:  Curr Treat Options Neurol       Date:  2020-02-03       Impact factor: 3.598

Review 4.  Radiologically isolated syndrome: from biological bases to practical management.

Authors:  Andres G Barboza; Edgar Carnero Contentti; Maria Celeste Curbelo; Mario Javier Halfon; Juan Ignacio Rojas; Berenice A Silva; Vladimiro Sinay; Santiago Tizio; Maria Celica Ysrraelit; Ricardo Alonso
Journal:  Neurol Sci       Date:  2021-01-25       Impact factor: 3.307

Review 5.  Radiologically Isolated Syndrome: A Review for Neuroradiologists.

Authors:  M Hosseiny; S D Newsome; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-06       Impact factor: 3.825

Review 6.  Drug Treatment of Clinically Isolated Syndrome.

Authors:  Moritz Förster; Jonas Graf; Jan Mares; Orhan Aktas; Hans-Peter Hartung; David Kremer
Journal:  CNS Drugs       Date:  2019-07       Impact factor: 6.497

7.  Amyloid-β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis.

Authors:  Mario Stampanoni Bassi; Sara Garofalo; Girolama A Marfia; Luana Gilio; Ilaria Simonelli; Annamaria Finardi; Roberto Furlan; Giulia M Sancesario; Jonny Di Giandomenico; Marianna Storto; Francesco Mori; Diego Centonze; Ennio Iezzi
Journal:  Front Mol Neurosci       Date:  2017-11-21       Impact factor: 5.639

Review 8.  Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

Authors:  Michael R Pranzatelli
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

9.  Multi-component relaxation in clinically isolated syndrome: Lesion myelination may predict multiple sclerosis conversion.

Authors:  Hagen H Kitzler; Hannes Wahl; Judith C Eisele; Matthias Kuhn; Henning Schmitz-Peiffer; Simone Kern; Brian K Rutt; Sean C L Deoni; Tjalf Ziemssen; Jennifer Linn
Journal:  Neuroimage Clin       Date:  2018-05-31       Impact factor: 4.881

10.  Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups.

Authors:  Gloria Donninelli; Valeria Studer; Laura Brambilla; Chiara Zecca; Daniele Peluso; Alice Laroni; Daniele Michelis; Renato Mantegazza; Paolo Confalonieri; Elisabetta Volpe
Journal:  Front Immunol       Date:  2021-03-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.